PMID- 33200717
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20240214
IS  - 2212-3989 (Electronic)
IS  - 1871-5265 (Print)
IS  - 1871-5265 (Linking)
VI  - 21
IP  - 6
DP  - 2021
TI  - Pharmacological Inhibition of MMP3 as a Potential Therapeutic Option for COVID-19 
      Associated Acute Respiratory Distress Syndrome.
PG  - e170721187996
LID - 10.2174/1871526520666201116100310 [doi]
AB  - The high mortality of coronavirus disease 2019 (COVID-19) patients is due to 
      their progression to cytokine-associated organ injuries, primarily the acute 
      respiratory distress syndrome (ARDS). The uncertainties in the molecular 
      mechanisms leading to the switch from the early virus infection to the advanced 
      stage ARDS is a major gridlock in therapeutic development to reduce mortality. 
      Previous studies in our laboratory have identified matrix metalloprotease-3 
      (MMP3) as an important mediator of bacterial lipopolysaccharide (LPS)-induced 
      ARDS, particularly in the exudative phase. Our studies have also reported 
      elevated plasma MMP3 activity levels in the ARDS patients and that inhibition of 
      MMP3 can reduce the severity of LPS-induced ARDS in mice. Given these 
      observations, targeting MMP3 could be a potential option to treat COVID-19 
      patients with ARDS, and measurement of MMP3 activity in the plasma may serve as a 
      biomarker for the early detection of ARDS in COVID-19 patients.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Kadry, Rana
AU  - Kadry R
AD  - Clinical and Experimental Therapeutics, College of Pharmacy, University of 
      Georgia and Charlie Norwood VA Medical Center, Augusta, GA 30912, United States.
FAU - Newsome, Andrea Sikora
AU  - Newsome AS
AD  - Clinical and Experimental Therapeutics, College of Pharmacy, University of 
      Georgia and Charlie Norwood VA Medical Center, Augusta, GA 30912, United States.
FAU - Somanath, Payaningal R
AU  - Somanath PR
AD  - Clinical and Experimental Therapeutics, College of Pharmacy, University of 
      Georgia and Charlie Norwood VA Medical Center, Augusta, GA 30912, United States.
LA  - eng
GR  - KL2 TR000455/TR/NCATS NIH HHS/United States
GR  - KL2 TR002381/TR/NCATS NIH HHS/United States
GR  - R01 HL103952/HL/NHLBI NIH HHS/United States
GR  - UL1 TR002378/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - United Arab Emirates
TA  - Infect Disord Drug Targets
JT  - Infectious disorders drug targets
JID - 101269158
RN  - 0 (Biomarkers)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Animals
MH  - Biomarkers
MH  - *COVID-19
MH  - Humans
MH  - Matrix Metalloproteinase 3
MH  - Mice
MH  - *Respiratory Distress Syndrome/drug therapy
MH  - SARS-CoV-2
PMC - PMC8551813
MID - NIHMS1748767
OTO - NOTNLM
OT  - ARDS
OT  - COVID-19
OT  - MMP3
OT  - biomarker
OT  - stromelysin1
OT  - syndrome.
COIS- CONFLICT OF INTEREST The authors declare no conflict of interest, financial or 
      otherwise.
EDAT- 2020/11/18 06:00
MHDA- 2021/10/16 06:00
PMCR- 2022/01/01
CRDT- 2020/11/17 08:39
PHST- 2020/06/15 00:00 [received]
PHST- 2020/09/13 00:00 [revised]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2020/11/17 08:39 [entrez]
PHST- 2022/01/01 00:00 [pmc-release]
AID - IDDT-EPUB-111515 [pii]
AID - 10.2174/1871526520666201116100310 [doi]
PST - ppublish
SO  - Infect Disord Drug Targets. 2021;21(6):e170721187996. doi: 
      10.2174/1871526520666201116100310.